BioInsights - Gaining critical characterization insights for development of CAR-T therapies for solid tumors

Gaining critical characterization insights for development of CAR-T therapies for solid tumors

Cell & Gene Therapy Insights 2019; 5(5), 803-817.


Published: 28 July 2019
Expert Roundtable
Sadik Kassim, Janani Krishnamurthy, Tamara Laskowski, John O’Rourke

Sadik Kassim

Executive Director, Kite Pharma, A Gilead Company

With a CV boasting the likes of Johnson & Johnson, the NIH, Novartis and Mustang Bio, Dr Sadik Kassim brings a wealth of experience and expertise spanning rare diseases, AAV-based gene therapy, immunotherapy, oncology, CAR-T cell therapies and CMC to his new role at Kite Pharma.

Janani Krishnamurthy

Senior Scientist, Atara Biotherapeutics

An expert in the fields of immunology, adoptive immunotherapy and neuroimmunology, Dr Janani Krishnamurthy enjoyed stints at MD Anderson, bluebird bio and TCR2 Therapeutics before taking on her current role leading EBV+ve CAR T cell pre-clinical initiatives for targeting solid tumours at Atara Biotherapeutics.

Tamara J Laskowski

Senior Research Scientist – Immunotherapy, Allison Group Department of Immunology, MD Anderson Cancer Center

Having originally joined Dr Laurence J.N. Cooper’s laboratory as a fellow, where her work focused on engineering stem cells with the goal of generating off-the-shelf NK and T-cell immunotherapies for targeting solid tumor malignancies, Dr Tamara Laskowski recently transitioned to Dr. James Allison’s Immunotherapy Platform at MD Anderson Cancer Center. In her new role Dr. Laskowski’s work primarily involves immune-monitoring of patients undergoing clinical trials in Immunotherapy and development of novel immunoassays.

John O’Rourke

Head of Product Development, Cell Analytics, Intellicyt, A Sartorius Company

John O’Rourke completed his Ph.D. in Biochemistry from The Ohio State University where he studied cancer biology and gene regulation. During his postdoctoral training at Nationwide’s Children’s Research Institute and the University of New Mexico, he continued his studies in cancer biology along with the development of viral and nanoparticle-based therapeutics. John O’Rourke completed his MBA at the Andersen School of Management at the University of New Mexico and joined IntelliCyt in 2017.